AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21331637
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish (5% sodium fluoride, Duraphat(®), Colgate) applied monthly for 6 months
Trial: 21331637
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (control) applied monthly for 6 months
Trial: 19458299
Drug: Straight-tip Tenckhoff
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Straight-tip Tenckhoff catheter with an artificial subcutaneous swan neck (TC)
Trial: 17635844
Drug: 1.87 mg
RxNorm normalized name: proline 1.87 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.87 mg triptorelin depot i.m. followed by daily s.c. injections of saline
Trial: 17635844
Drug: Reduced-dose daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose daily buserelin (0.5 mg initially, reduced to 0.25 mg)
Trial: 11579354
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of oral conjugated estrogens (Premarin) per day for 4 to 6 weeks
Trial: 9848785
Drug: Irbesartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (100 mg/d)
Trial: 9848785
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg/d) + Indomethacin (75 mg twice a day)
Trial: 9848785
Drug: Irbesartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (100 mg/d) + Indomethacin (75 mg twice a day)
Trial: 28967201
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg solifenacin with 150 mg aclatonium once daily for 8 weeks
Trial: 28967201
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg solifenacin with placebo once daily for 8 weeks
Trial: 25382452
Drug: Carvedilol (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (titrated from 3.125 mg twice daily to 6.25 mg twice daily)
Trial: 23237631
Drug: Acenocoumarol dosing
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocoumarol dosing algorithm based on demographic, clinical, and pharmacogenetic variables (VKORC1, CYP2C9, CYP4F2, ApoE)
Trial: 23237631
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (control group) with scheduled and adjusted acenocoumarol dose following common clinical practice
Trial: 23237631
Drug: Acenocoumarol dosing
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocoumarol dosing algorithm
Trial: 17876425
Drug: Sedation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation with intravenous midazolam (5 mg for those under 65 years, 2.5 mg for those aged 65 years or more)
Trial: 16230678
Drug: PVI FU
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVI FU 225 mg/m2/d for 5 d/wk for six cycles during RT
Trial: 11988242
Drug: Interferon beta‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1b 250 microg administered every other day
Trial: 11988242
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a 30 microg administered once a week
Trial: 7569506
Drug: Dose-response information
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-response information to support drug registration (especially dose/toxicity relationships)
Trial: 7569506
Drug: ICH Draft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICH Draft Guideline 3 on the extent of population exposure required to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions
Trial: 1978233
Drug: bopindolol (1‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bopindolol (1‐3 mg daily)
Trial: 1978233
Drug: metoprolol (100‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (100‐300 mg daily in two divided doses)
Trial: 336412
Drug: Luteinizing hormone-releasing
RxNorm normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone (LH-RH)
Trial: 336412
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (LH-RH, hCG, and placebo)
Trial: 29119732
Drug: Warfarin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (Group W, n=30)
Trial: 29119732
Drug: Warfarin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (Group W)
Trial: 22985692
Drug: Inhaled aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aztreonam lysine (AZLI) 75 mg (three-times/day)
Trial: 22985692
Drug: Inhaled tobramycin
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin nebulizer solution (TNS) 300 mg (twice/day)
Trial: 16764551
Drug: Placebo techniques
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo techniques developed to mimic spinal manipulative therapy
Trial: 11713618
Drug: Olanzapine 2.5
RxNorm normalized name: olanzapine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 2.5 mg and 5 mg
Trial: 1089913
Drug: Clonazepam (0.028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (0.028 to 0.111 mg/kg)
Trial: 28760794
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist trigger and single vitrified-warmed blastocyst transfer in a subsequent hCG triggered natural menstrual cycle
Trial: 21525194
Drug: Galactooligosaccharides 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactooligosaccharides 2.5 g
Trial: 21525194
Drug: Galactooligosaccharides 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactooligosaccharides 5.0 g
Trial: 21525194
Drug: Galactooligosaccharides 0
RxNorm normalized name: fructooligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactooligosaccharides 0 g (Control)
Trial: 11530125
Drug: Mifepristone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 100 mg followed by misoprostol 400 microg orally (group 1)
Trial: 11530125
Drug: Mifepristone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 100 mg followed by misoprostol 800 microg vaginally (group 2)
Trial: 12959295
Drug: Nifedipine with
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine with grapefruit juice (200 ml double strength)
Trial: 12959295
Drug: Nifedipine with
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine with quercetin (400 mg)
Trial: 3126890
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy (n = 32)
Trial: 3126890
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy (n = 30)
Trial: 3126890
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy (n = 30)
Trial: 28350652
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (topical application during surgery)
Trial: 25015650
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy (RAT) - 3 conventional therapy sessions and 2 robot-assisted sessions per week over 8 weeks
Trial: 25015650
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy - 5 sessions per week over 8 weeks
Trial: 21205399
Drug: Oportunidades food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oportunidades food supplement (OFS)
Trial: 8993761
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of anti-herpes dialysate (AH-DLE)
Trial: 8993761
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of anti-herpes dialysate (AH-DLE)
Trial: 8993761
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of anti-herpes dialysate (AH-DLE)
Trial: 6379630
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aqueous nasal spray (100 micrograms into each nostril twice daily)
Trial: 6379630
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate pressurized nasal spray (100 micrograms into each nostril twice daily)
Trial: 21902621
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) 75 mg qd then 25 mg qd
Trial: 21902621
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 600 mg qd
Trial: 20935517
Drug: Monovalent A
RxNorm normalized name: rotavirus, monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent A (H1N1) pandemic vaccine (Panenza®)
Trial: 20935517
Drug: Trivalent split
RxNorm normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent split inactivated vaccine (Vaxigrip®)
Trial: 18595959
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide (32 microg per nostril at bedtime)
Trial: 16208072
Drug: Drug misuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug misuse and abuse prevention program (1 hour, once a week for 5 weeks)
Trial: 10999082
Drug: Sequential Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Drug Monotherapy (SDM)
Trial: 10999082
Drug: Step Care
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step Care Therapy (SCT)
Trial: 8527293
Drug: Lactose (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (various doses)
Trial: 8527293
Drug: Placebo (empty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (empty dose)
Trial: 2255839
Drug: Ivermectin 50
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 50 mcg/kg
Trial: 28098838
Drug: Silymarin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (oral doses)
Trial: 19479385
Drug: Satranidazole mucoadhesive
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Satranidazole mucoadhesive gel (SC30 formulation)
Trial: 19479385
Drug: Marketed metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marketed metronidazole gel (Metrogyl gel)
Trial: 3221374
Drug: Nitrendipine 10-20
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 10-20 mg per day
Trial: 3221374
Drug: Oxprenolol 160
RxNorm normalized name: oxprenolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 160 mg per day
Trial: 30231990
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation therapy (LDRT) - 6 × 1 Gy in 2 weeks
Trial: 30231990
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment - 6 × 0 Gy in 2 weeks
Trial: 26418670
Drug: Interferon and
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon and ribavirin treatment for 12 weeks (Finnish patients)
Trial: 26418670
Drug: Interferon and
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon and ribavirin treatment for 12-16 weeks (Swedish patients)
Trial: 19034033
Drug: Ambroxol administered
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol administered orally for a week before and after surgery (n = 25)
Trial: 8403177
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg sublingual triazolam
Trial: 3709641
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of PY 108‐068
Trial: 3709641
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of PY 108‐068
Trial: 21798721
Drug: Ziprasidone (80-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (80-160 mg/d) plus mood stabilizer (lithium or valproate)
Trial: 8677906
Drug: Ifosfamide 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 1.5 g/m2 and mesna at 30% of the ifosfamide dose, administered i.v. daily for 5 days every 21 days.
Trial: 1815962
Drug: Verapamil (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (after oral pretreatment)
Trial: 6824300
Drug: 0.5% plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% plain bupivacaine (3.5 ml)
Trial: 6824300
Drug: 0.5% plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% plain bupivacaine (3 ml)
Trial: 31271569
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine A 0.05% (twice a day for 10 days before and 10 days after surgery)
Trial: 31271569
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (31 patients who did not receive cyclosporine treatment)
Trial: 12205259
Drug: Rectal acetaminophen
RxNorm normalized name: acetaminophen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetaminophen 15 mg/kg (Group A)
Trial: 12205259
Drug: Rectal acetaminophen
RxNorm normalized name: acetaminophen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetaminophen 30 mg/kg (Group B)
Trial: 12205259
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen 15 mg/kg (Group C)
Trial: 9809555
Drug: T-20 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-20 (100 mg twice daily)
Trial: 9809555
Drug: T-20 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-20 (various doses)
Trial: 7665721
Drug: Lornoxicam 32
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 32 mg
Trial: 25369608
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (mean dose 7-9 g)
Trial: 19432498
Drug: olmesartan/amlodipine 40/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan/amlodipine 40/5 mg
Trial: 19432498
Drug: olmesartan/amlodipine 40/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan/amlodipine 40/10 mg
Trial: 19432498
Drug: olmesartan/amlodipine/HCTZ 40/10/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan/amlodipine/HCTZ 40/10/12.5 mg
Trial: 7060825
Drug: UDCA 12
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 12 mg/kg/day
Trial: 7060825
Drug: UDCA 8
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 8 mg/kg/day
Trial: 7060825
Drug: UDCA 4
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 4 mg/kg/day
Trial: 22307572
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) in women in 2008
Trial: 20973712
Drug: Aripiprazole (flexibly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (flexibly dosed 2-15 mg/day)
Trial: 20973712
Drug: Aripiprazole (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (fixed dose 5, 10, or 15 mg/day)
Trial: 20973712
Drug: Placebo (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (fixed dose)
Trial: 20973712
Drug: Aripiprazole (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (both dosing regimens)
Trial: 17052252
Drug: Doxazosin (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (standard tablet)
Trial: 17052252
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS (controlled release formulation)
Trial: 17052252
Drug: Doxazosin, Tamsulosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin, Tamsulosin, Terazosin, Prazosin (α1-receptor antagonists)
Trial: 16230074
Drug: Entecavir 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.1 mg daily
Trial: 12123333
Drug: Intramuscular depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular depot medroxyprogesterone acetate (MPA) 500 mg on days 1, 14, and 28
Trial: 12123333
Drug: Oral megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral megestrol acetate 40 mg daily for 6 weeks
Trial: 7836079
Drug: Radiotherapy 60
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy 60 Gy in 30 fractions in 6 weeks plus carboplatin 350 mg/m2 during weeks 1 and 5 (arm III)
Trial: 7836079
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy 60 Gy in 30 fractions in 3 weeks plus carboplatin 350 mg/m2 during week 1 (arm IV)
Trial: 2136775
Drug: Nebulised ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised ipratropium bromide plus 4‐hourly fenoterol (group I, 50 patients)
Trial: 2136775
Drug: 2‐hourly fenoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐hourly fenoterol (group II, 50 patients)
Trial: 2136775
Drug: 4‐hourly fenoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐hourly fenoterol (group III, 45 patients)
Trial: 26389597
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus memory support (CT + MS; n = 22)
Trial: 26389597
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy as-usual (CT-as-usual; n = 20)
Trial: 26389597
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus memory support (CT + MS)
Trial: 26389597
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy as-usual (CT-as-usual)
Trial: 24406614
Drug: Scopolamine transdermal
RxNorm normalized name: scopolamine Transdermal System
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine transdermal patch, dosage and duration not specified
Trial: 23031065
Drug: Exercise prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise prescription (individually tailored home-based exercise prescriptions for 6 months)
Trial: 20826257
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg/d; TEL, n = 25)
Trial: 17519582
Drug: Tomato extract
RxNorm normalized name: TOMATO EXTRACT CONTAINING LYCOPENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato extract (TE) 360 mg per day for 8 weeks
Trial: 10434817
Drug: Patient-controlled i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled i.v. morphine (PCIM)
Trial: 1977703
Drug: H2-receptor antagonists
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine)
Trial: 1977703
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (omeprazole)
Trial: 82356
Drug: 0.6 g
RxNorm normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g of oral zinc sulphate daily
Trial: 24918475
Drug: 2.0 mL
RxNorm normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mL oral 24% sucrose (n=29)